الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Cisplatin is an approved cancer therapeutic drug used to treat many solid tumors but its accumulation in the kidney, which causes nephrotoxicity, limits its clinical use. Therefore, investigators seek new alternatives to cisplatin that may be more effective and/or safer. The aim of this work is the study of the antitumor effect of complexation of Schiff base 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide (HEPTS) with copper on Ehrlich solid tumor-bearing mice in comparison to cancer therapeutic drug cisplatin. The experiment was run using eleven adult female Swiss albino mice. Mice were allocated into eleven groups (n =10 mice). Healthy control, EAC control (untreated tumor), EAC+cisplatin, EAC+HEPTS, EAC+ complex (with different doses), Healthy+HEPTS, Healthy+ complex and Healthy+solvent. After scarification, blood samples, liver organs, and solid tumors were collected. Tumor weights and volumes were registered. The concentrations of malondialdehyde (MDA), reduced glutathione (GSH), SOD, catalase (CAT), total antioxidant capacity (TAC), nitric oxide (NO), uric acid, creatinine, and urea were assessed. Median survival time (MST) and the percentage increase in lifespan (%ILS) were also calculated. Treatment of tumorized mice with complex significantly reduced both tumor volume and weight while it significantly increased the MST, antioxidant marks and prolonged the %ILS. It also, significantly reduced MAD, creatinine, urea, uric acid, and NO levels. Compared to cisplatin, complex effects were better. Our results recommend complex as one of the probable cisplatin-alternatives for tumor treatment after more validation.